Green light laser enucleation of the prostate with early apical release is safe and effective: single center experience and revision of the literature.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Aug 2022
Historique:
pubmed: 31 3 2021
medline: 20 7 2022
entrez: 30 3 2021
Statut: ppublish

Résumé

Green Light laser enucleation of the prostate (GreenLEP) is an endoscopic treatment to treat bladder outlet obstruction in men with large prostate (>100 cc). Herein, we describe our GreenLEP series and describe its safety and efficacy. Between February 2014 and April 2019, 120 patients from a single center underwent en-bloc GreenLEP with early apical release. All procedures were performed with the AMS XPS laser generator (set: 120 W for vaporization and 20 W for coagulation). Morcellation was carried out with the Wolf Piranha morcellator. Data concerning the pre-, intra- and postoperative outcomes were prospectively collected. The follow-up data at 6, 12 months and at the last control were collected. The median age was 66.0 (IQR: 61.0-71.0) years; 37.5% of the patients were under antiplatelet/anticoagulant therapy, 15.0% had indwelling catheter history. The median prostate volume and the baseline PSA value were 98.5 mL (IQR 83.0-130.0) and 4.2 ng/mL (IQR: 3.2-6.8), respectively. The median operative and lasing time were 65.0 (IQR: 51.0-83.5) and 6.0 (IQR: 6.0-10.0) minutes, respectively. In the postoperative period 1 patient was transfused. The median follow-up was 18.0 (IQR: 12.0-39.5) months. All patients had significant improvement in terms of improvement of uroflowmetry (median from 9 mL/sec [IQR 7.8, 11.0] to 20.0 [IQR 18.0, 22.0], P<0.001) and symptoms control (IPSS median score from 26.0 mL/sec [IQR 22.0, 28.0] to 7.0 [IQR 6.0, 8.0], P<0.001]) over time. After 12 months 1 patient complained of stress incontinence (1 pad/day) and 1 of "de novo" wet urgency. En-bloc GreenLEP with early apical release is a safe and effective procedure even for large volume prostates. It allows us to limit the use of laser energy and shorten the operating times with stable and satisfactory long-term outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Green Light laser enucleation of the prostate (GreenLEP) is an endoscopic treatment to treat bladder outlet obstruction in men with large prostate (>100 cc). Herein, we describe our GreenLEP series and describe its safety and efficacy.
METHODS METHODS
Between February 2014 and April 2019, 120 patients from a single center underwent en-bloc GreenLEP with early apical release. All procedures were performed with the AMS XPS laser generator (set: 120 W for vaporization and 20 W for coagulation). Morcellation was carried out with the Wolf Piranha morcellator. Data concerning the pre-, intra- and postoperative outcomes were prospectively collected. The follow-up data at 6, 12 months and at the last control were collected.
RESULTS RESULTS
The median age was 66.0 (IQR: 61.0-71.0) years; 37.5% of the patients were under antiplatelet/anticoagulant therapy, 15.0% had indwelling catheter history. The median prostate volume and the baseline PSA value were 98.5 mL (IQR 83.0-130.0) and 4.2 ng/mL (IQR: 3.2-6.8), respectively. The median operative and lasing time were 65.0 (IQR: 51.0-83.5) and 6.0 (IQR: 6.0-10.0) minutes, respectively. In the postoperative period 1 patient was transfused. The median follow-up was 18.0 (IQR: 12.0-39.5) months. All patients had significant improvement in terms of improvement of uroflowmetry (median from 9 mL/sec [IQR 7.8, 11.0] to 20.0 [IQR 18.0, 22.0], P<0.001) and symptoms control (IPSS median score from 26.0 mL/sec [IQR 22.0, 28.0] to 7.0 [IQR 6.0, 8.0], P<0.001]) over time. After 12 months 1 patient complained of stress incontinence (1 pad/day) and 1 of "de novo" wet urgency.
CONCLUSIONS CONCLUSIONS
En-bloc GreenLEP with early apical release is a safe and effective procedure even for large volume prostates. It allows us to limit the use of laser energy and shorten the operating times with stable and satisfactory long-term outcomes.

Identifiants

pubmed: 33781016
pii: S2724-6051.21.04145-X
doi: 10.23736/S2724-6051.21.04145-X
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

467-474

Auteurs

Giovanni Ferrari (G)

Department of Urology, Hesperia Hospital, CURE Group, Modena, Italy.

Salvatore Rabito (S)

Department of Urology, Hesperia Hospital, CURE Group, Modena, Italy - salvorabito@hotmail.it.
Department of Urology, Sant'Agostino Estense Hospital, Modena, Italy.

Lorenzo Gatti (L)

Department of Urology, Hesperia Hospital, CURE Group, Modena, Italy.

Nicolas N Ntep (NN)

Department of Urology, Hesperia Hospital, CURE Group, Modena, Italy.

Ferdinando D Vitelli (FD)

Department of Urology, Hesperia Hospital, CURE Group, Modena, Italy.

Michele Marchioni (M)

Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy.

Bernardo M Rocco (BM)

Department of Urology, Sant'Agostino Estense Hospital, Modena, Italy.

Salvatore Micali (S)

Department of Urology, Sant'Agostino Estense Hospital, Modena, Italy.

Riccardo Ferrari (R)

Department of Urology, Sant'Agostino Estense Hospital, Modena, Italy.

Luca Cindolo (L)

Department of Urology, Hesperia Hospital, CURE Group, Modena, Italy.
Department of Urology, Villa Stuart Private Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH